Show simple item record

dc.contributor.authorZhao, AZ
dc.contributor.authorTohidkia, MR
dc.contributor.authorSiegel, DL
dc.contributor.authorCoukos, G
dc.contributor.authorOmidi, Y
dc.date.accessioned2018-08-26T07:29:37Z
dc.date.available2018-08-26T07:29:37Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/47073
dc.description.abstractPhage display technology (PDT), a combinatorial screening approach, provides a molecular diversity tool for creating libraries of peptides/proteins and discovery of new recombinant therapeutics. Expression of proteins such as monoclonal antibodies (mAbs) on the surface of filamentous phage can permit the selection of high affinity and specificity therapeutic mAbs against virtually any target antigen. Using a number of diverse selection platforms (e.g. solid phase, solution phase, whole cell and in vivo biopannings), phage antibody libraries (PALs) from the start point provides great potential for the isolation of functional mAb fragments with diagnostic and/or therapeutic purposes. Given the pivotal role of PDT in the discovery of novel therapeutic/diagnostic mAbs, in the current review, we provide an overview on PALs and discuss their impact in the advancement of engineered mAbs.
dc.language.isoEnglish
dc.relation.ispartofCRITICAL REVIEWS IN BIOTECHNOLOGY
dc.subjectCancer
dc.subjectimmunotherapy
dc.subjectphage antibody library
dc.subjectphage display technology
dc.subjectrecombinant monoclonal antibody
dc.titlePhage antibody display libraries: a powerful antibody discovery platform for immunotherapy
dc.typeReview
dc.citation.volume36
dc.citation.issue2
dc.citation.spage276
dc.citation.epage289
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.3109/07388551.2014.958978


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record